The MaxCmin trial will evaluate the safety and efficacy of indinavir/ritonavir (800/100 mg bid) versus saquinavir/ritonavir (1000/100 mg bid) in adult HIV-1 infected patients. It is an open-label, multi-centre trial including 317 patients from Europe as well as North- and South America. Randomization decided the treatment assigned to the individual patient.

The first patient was randomized o­n 5 September 2000. Recruitment was closed o­n 20 March 2001 with 317 patients randomised.

The interim analysis was presented at EACS Conference, Athens, October 2001.

Presentation of final results o­n toxicity was presented at the XIV International AIDS Conference in Barcelona 2002.

Final analysis was presented at the Sixth International Congress o­n Drug Therapy in HIV Infection in Glasgow 2002.

Data from the pharmacokinetic substudy and from the substudy o­n clinical lipodystrophy and retinoid syndrome were presented at the 9th EACS, Warsaw, 2003.

Updated: 20 Dec 2005